University of Leicester
Browse

The Primary-Secondary Care Partnership to Improve Outcomes in Chronic Kidney Disease (PSP-CKD) Study: A Cluster Randomized Trial in Primary Care

Download (711.16 kB)
Version 2 2020-03-24, 09:46
Version 1 2020-03-24, 09:43
journal contribution
posted on 2020-03-24, 09:46 authored by Rupert W Major, Celia Brown, David Shepherd, Stephen Rogers, Warren Pickering, Graham L Warwick, Shaun Barber, Nuzhat B Ashra, Tom Morris, Nigel J Brunskill

Background Most patients with CKD are managed in the community. Whether nurse-led CKD management programs improve outcomes in patients with CKD in primary care is unclear.

Methods To assess the effect of such a program on the rate of renal function decline in patients with CKD (stages 3–5) in primary care in the United Kingdom, we conducted a cluster randomized trial, the Primary-Secondary Care Partnership to Improve Outcomes in Chronic Kidney Disease study. A software program designed for the study created a data file of patients with CKD in participating practices. In 23 intervention practices (11,651 patients), a CKD nurse practitioner worked with nominated practice leads to interpret the data file and implement guideline-based patient-level CKD management interventions. The 23 control practices (11,706 patients) received a data file but otherwise, continued usual CKD care. The primary outcome was defined at the cluster (practice) level as the change from baseline of the mean eGFR of the patients with CKD at 6-month intervals up to 42 months. Secondary outcomes included numbers of patients coded for CKD, mean BP, numbers of patients achieving National Institute for Health and Care Excellence BP targets for CKD, and proteinuria measurement.

Results After 42 months, eGFR did not differ significantly between control and intervention groups. CKD- and proteinuria-related coding improved significantly along with the number of patients achieving BP targets in the intervention group versus usual care.

Conclusions CKD management programs in primary care may not slow progression of CKD, but they may significantly improve processes of care and potentially decrease the cardiovascular disease burden in CKD and related costs.

Funding

PSP-CKD was funded initially by the CLAHRC LNR and then by CLAHRC-East Midlands. CB is supported by CLAHRC-West Midlands. The study was subject to external peer review by the NIHR CLAHRC Scientific Committee prior to funding approval.

History

Citation

JASN July 2019, 30 (7) 1261-1270; DOI: https://doi.org/10.1681/ASN.2018101042

Version

  • AM (Accepted Manuscript)

Published in

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Volume

30

Issue

7

Pagination

1261 - 1270 (10)

Publisher

AMER SOC NEPHROLOGY

issn

1046-6673

eissn

1533-3450

Acceptance date

2019-03-28

Copyright date

2019

Available date

2019-06-28

Publisher version

https://jasn.asnjournals.org/content/30/7/1261.abstract

Spatial coverage

United States

Language

English

Usage metrics

    University of Leicester Publications

    Categories

    No categories selected

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC